CA2188385C - Dosage forms and method for ameliorating male erectile dysfunction - Google Patents
Dosage forms and method for ameliorating male erectile dysfunction Download PDFInfo
- Publication number
- CA2188385C CA2188385C CA002188385A CA2188385A CA2188385C CA 2188385 C CA2188385 C CA 2188385C CA 002188385 A CA002188385 A CA 002188385A CA 2188385 A CA2188385 A CA 2188385A CA 2188385 C CA2188385 C CA 2188385C
- Authority
- CA
- Canada
- Prior art keywords
- apomorphine
- penile
- patient
- acid addition
- addition salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Abstract
Pyschogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, whithout substantial undesirable side effects, by sublingual administration of apomorphine dosage forms that contain about 2.5 to about 10 milligrams of apomorphine and dissolve within a time period of about 2 to about 5 minutes.
Description
~I88385 DOSAGE FORMS AND METHOD FOR AMELIORATING
MALE ERECTILE DYSFUNCTION
Field of the Invention This invention, in one aspect, relates to dosage forms and methods for ameliorating erectile dysfunction in psychogenic male patients. In another aspect this invention relates to diagnosis of erectile dysfunction. More particularly, this invention relates to the use of apomorphine-containing compositions for amelioration of erectile dysfunction in psychogenic male patients and for diagnostic purposes.
Backctround of the Invention A normal erection occurs as a result of a coordinated vascular event in the penis. This is usually triggered neurally and consists of vasodilation and smooth muscle relaxation in the penis and its supplying arterial vessels. Arterial inflow causes enlargement of the substance of the corpora cawernosa.
Venous outflow is trapped by this enlargement, permitting sustained high blood pressures in the penis sufficient to cause rigidity. Muscles in the perineum also assist in creating and maintaining penile rigidity.
Erection may be induced centrally in the nervous system by sexual thoughts or fantasy, and is usually reinforced locally by reflex mechanisms. Erectile mechanics are substantially similar in the female for the clitoris.
Impotence or male erectile dysfunction is defined as the inability to achieve and sustain an erection sufficient for intercourse. Impotence in any given case can result from psychological disturbances (psychogenic), from physiological abnormalities in general (organic), from neurological disturbances (neurogenic), hormonal deficiencies (endocrine) or from a combination of the foregoing.
WO 95/28930 ~ ~ PCTIUS95104897 These descriptions are not exact, however.
There is currently no standardized method of diagnosis or treatment. As used herein, psychogenic impotence is defined as functional impotence with no apparent overwhelming organic basis. It may be characterized by an ability to have an erection in response to, some stimuli (e. g., masturbation, spontaneous nocturnal, spontaneous early morning, video erotica, etc.) but not others (e. g., partner or spousal attention).
Various methods for the treatment of impotence have been suggested, including external devices, for example, tourniquets (see U.S. Patent No. 2,818,855).
In addition, penile implants, such as hinged or solid rods and inflatable, spring driven or hydraulic models, have been used for some time. The administration of erection effecting and enhancing drugs is taught in U.S.
Patent No. 4,127,118 to LaTorre. That patent teaches a method of treating male impotence by injecting into the penis an appropriate vasodilator, in particular, an adrenergic blocking agent or a smooth muscle relaxant to effect and enhance an erection. More recently, U.S.
Patent No. 4,801,587 to Voss et al. teaches the application of an ointment to relieve impotence. The ointment consists of the vasodilators papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine, or phentolamine and a carrier to assist absorption of the primary agent through the skin. U.S. Patent No.
5,256,652 to El-Rashidy teaches the use of an aqueous topical composition of a vasodilator such as papaverine together with hydroxypropyl-~i-cyclodextrin.
Recently the effect of apomorphine on penile tumescence in male patients afflicted with psychogenic impotence has been studied. These studies show that while apomorphine can indeed induce an erection in a psychogenic male patient, the apomorphine dose required T __~.. _ ... _ . _. T.~~_ . _...~. _..._...._. .T. .....
2_ I ~~385 to achieve a significant erectile response is usually accompanied by nausea or other serious undesirable side effects such as hypertension, flushing and diaphoresis.
The specific mechanisms by which apomorphine acts to produce an erectile response in a human patient are not yet completely understood, however.
Moreover, apomorphine has been shown to have very poor oral bioavailability. See, for example, Baldessarini et al., in Gessa et al., eds., Apomorphine and Other Dopaminomimetics, Basic Pharmacoloav, Vol. 1, Raven Press, N.Y. (1981), pp. 219-228.
Thus the search is continuing for an effective treatment of psychogenic impotence in male patients as well as for diagnostic methods that can identify such patients. It has now been found that certain delivery systems for apomorphine can provide a practical therapeutic and/or diagnostic "window" while reducing the likelihood of undesirable side effects.
Summary of the Invention It has now been found that, for an optimal erectile response, steady state circulating serum and mid-brain tissue levels of apomorphine are to be maintained within a relatively closely defined range.
Sublingual apomorphine dosage forms, usually containing about 2.5 to about 10 milligrams of apomorphine, and dissolving in water within a time period of at least about 2 minutes but less than about 10 minutes, preferably about 3 minutes to about 5 minutes, have been found to be effective in male patients suffering from psychogenic erectile dysfunction for the induction and maintenance of an erection sufficient for intercourse (i.e., vaginal penetration) without nausea or other undesirable side effects. The apomorphine is administered sublingually, preferably about 15 to about 20 minutes prior to sexual activity, WO 95/28930 ~ 1 ~ PCT/US95/04897 and so as to maintain a predetermined circulating serum levels and mid-brain tissue levels of apomorphine during the period of sexual activity.
The foregoing sublingual apomorphine dosage forms are also suitable for screening patients complaining of erectile dysfunction so ws to identify patients of psychogenic etiology.
Brief Description of the Drawinas In the drawings, FIGURE 1 is a graphical representation of mean erectile function, expressed as RIGISCANT~"'~ monitor value, as a function of apomorphine dose;
FIGURE 2 is a bar graph depicting the percent successful erectile function for placebo, 3-milligram apomorphine dose, and 4-milligram apomorphine dose under erotic and neutral conditions; and FIGURE 3 is a bar graph presenting yet another comparison of erectile function noted in Pilot Study #4 in terms of RIGISCANT~N~ monitor score versus placebo, 3 milligrams of apomorphine and 4 milligrams of apomorphine under erotic and neutral conditions.
Detailed Description of Preferred Embodiments Apomorphine is a dopamine receptor agonist that has a recognized use as an emetic when administered subcutaneously in about a 5-milligram dose. For the purposes of the present invention, apomorphine or a similarly acting dopamine receptor agonist is administered in an amount sufficient to excite cells in the mid-brain region of the patient but with minimal side effects. This cell excitation is believed to be part of a cascade of stimulation that is likely to include neurotransmission with serotonin and oxytocin.
The dopamine receptors in the mid-brain region of a patient can be stimulated to a degree sufficient to cause an erection by the sublingual administration of ....T___ , T.. _...
MALE ERECTILE DYSFUNCTION
Field of the Invention This invention, in one aspect, relates to dosage forms and methods for ameliorating erectile dysfunction in psychogenic male patients. In another aspect this invention relates to diagnosis of erectile dysfunction. More particularly, this invention relates to the use of apomorphine-containing compositions for amelioration of erectile dysfunction in psychogenic male patients and for diagnostic purposes.
Backctround of the Invention A normal erection occurs as a result of a coordinated vascular event in the penis. This is usually triggered neurally and consists of vasodilation and smooth muscle relaxation in the penis and its supplying arterial vessels. Arterial inflow causes enlargement of the substance of the corpora cawernosa.
Venous outflow is trapped by this enlargement, permitting sustained high blood pressures in the penis sufficient to cause rigidity. Muscles in the perineum also assist in creating and maintaining penile rigidity.
Erection may be induced centrally in the nervous system by sexual thoughts or fantasy, and is usually reinforced locally by reflex mechanisms. Erectile mechanics are substantially similar in the female for the clitoris.
Impotence or male erectile dysfunction is defined as the inability to achieve and sustain an erection sufficient for intercourse. Impotence in any given case can result from psychological disturbances (psychogenic), from physiological abnormalities in general (organic), from neurological disturbances (neurogenic), hormonal deficiencies (endocrine) or from a combination of the foregoing.
WO 95/28930 ~ ~ PCTIUS95104897 These descriptions are not exact, however.
There is currently no standardized method of diagnosis or treatment. As used herein, psychogenic impotence is defined as functional impotence with no apparent overwhelming organic basis. It may be characterized by an ability to have an erection in response to, some stimuli (e. g., masturbation, spontaneous nocturnal, spontaneous early morning, video erotica, etc.) but not others (e. g., partner or spousal attention).
Various methods for the treatment of impotence have been suggested, including external devices, for example, tourniquets (see U.S. Patent No. 2,818,855).
In addition, penile implants, such as hinged or solid rods and inflatable, spring driven or hydraulic models, have been used for some time. The administration of erection effecting and enhancing drugs is taught in U.S.
Patent No. 4,127,118 to LaTorre. That patent teaches a method of treating male impotence by injecting into the penis an appropriate vasodilator, in particular, an adrenergic blocking agent or a smooth muscle relaxant to effect and enhance an erection. More recently, U.S.
Patent No. 4,801,587 to Voss et al. teaches the application of an ointment to relieve impotence. The ointment consists of the vasodilators papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine, or phentolamine and a carrier to assist absorption of the primary agent through the skin. U.S. Patent No.
5,256,652 to El-Rashidy teaches the use of an aqueous topical composition of a vasodilator such as papaverine together with hydroxypropyl-~i-cyclodextrin.
Recently the effect of apomorphine on penile tumescence in male patients afflicted with psychogenic impotence has been studied. These studies show that while apomorphine can indeed induce an erection in a psychogenic male patient, the apomorphine dose required T __~.. _ ... _ . _. T.~~_ . _...~. _..._...._. .T. .....
2_ I ~~385 to achieve a significant erectile response is usually accompanied by nausea or other serious undesirable side effects such as hypertension, flushing and diaphoresis.
The specific mechanisms by which apomorphine acts to produce an erectile response in a human patient are not yet completely understood, however.
Moreover, apomorphine has been shown to have very poor oral bioavailability. See, for example, Baldessarini et al., in Gessa et al., eds., Apomorphine and Other Dopaminomimetics, Basic Pharmacoloav, Vol. 1, Raven Press, N.Y. (1981), pp. 219-228.
Thus the search is continuing for an effective treatment of psychogenic impotence in male patients as well as for diagnostic methods that can identify such patients. It has now been found that certain delivery systems for apomorphine can provide a practical therapeutic and/or diagnostic "window" while reducing the likelihood of undesirable side effects.
Summary of the Invention It has now been found that, for an optimal erectile response, steady state circulating serum and mid-brain tissue levels of apomorphine are to be maintained within a relatively closely defined range.
Sublingual apomorphine dosage forms, usually containing about 2.5 to about 10 milligrams of apomorphine, and dissolving in water within a time period of at least about 2 minutes but less than about 10 minutes, preferably about 3 minutes to about 5 minutes, have been found to be effective in male patients suffering from psychogenic erectile dysfunction for the induction and maintenance of an erection sufficient for intercourse (i.e., vaginal penetration) without nausea or other undesirable side effects. The apomorphine is administered sublingually, preferably about 15 to about 20 minutes prior to sexual activity, WO 95/28930 ~ 1 ~ PCT/US95/04897 and so as to maintain a predetermined circulating serum levels and mid-brain tissue levels of apomorphine during the period of sexual activity.
The foregoing sublingual apomorphine dosage forms are also suitable for screening patients complaining of erectile dysfunction so ws to identify patients of psychogenic etiology.
Brief Description of the Drawinas In the drawings, FIGURE 1 is a graphical representation of mean erectile function, expressed as RIGISCANT~"'~ monitor value, as a function of apomorphine dose;
FIGURE 2 is a bar graph depicting the percent successful erectile function for placebo, 3-milligram apomorphine dose, and 4-milligram apomorphine dose under erotic and neutral conditions; and FIGURE 3 is a bar graph presenting yet another comparison of erectile function noted in Pilot Study #4 in terms of RIGISCANT~N~ monitor score versus placebo, 3 milligrams of apomorphine and 4 milligrams of apomorphine under erotic and neutral conditions.
Detailed Description of Preferred Embodiments Apomorphine is a dopamine receptor agonist that has a recognized use as an emetic when administered subcutaneously in about a 5-milligram dose. For the purposes of the present invention, apomorphine or a similarly acting dopamine receptor agonist is administered in an amount sufficient to excite cells in the mid-brain region of the patient but with minimal side effects. This cell excitation is believed to be part of a cascade of stimulation that is likely to include neurotransmission with serotonin and oxytocin.
The dopamine receptors in the mid-brain region of a patient can be stimulated to a degree sufficient to cause an erection by the sublingual administration of ....T___ , T.. _...
apomorphine over a time period in the range of about 2 to about 10 minutes. The amount of apomorphine administered sublingually over this time period preferably is in the range of about 25 micrograms per kilogram (ug/kg) of body weight to about 60 ~g/kg of body weight.
The apomorphine is administered preferably about 15 to about 20 minutes prior to sexual activity.
Apomorphine can be represented by the formula i Ha \ N
HO ~ \
OH
and exists in a free base form or as an acid addition salt. For the purposes of the present invention apomorphine hydrochloride is preferred; however, other pharmacologically acceptable moieties thereof can be utilized as well. The term "apomorphine" as used herein includes the free base form of this compound as well as the pharmacologically acceptable acid addition salts thereof. In addition to the hydrochloride salt, other acceptable acid addition salts are the hydrobromide, the hydroiodide, the bisulfate, the phosphate, the acid phosphate, the lactate, the citrate, the tartarate, the salicylate, the succinate, the maleate, the gluconate, and the like.
Illustrative preferred sublingual dosage forms are set forth in Table I, below.
1W0 95/28930 2 ~ 8 8 3 8 5 P~~S95/04897 TABLE I
150-Milligram Apomorphine Hydrochloride Sublingual Tablets 3-m Tc~ ablet Apomorphine Hydrochloride 2.00 wt-Mannitol 66.67 wt-Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-Avicel*PH102 15.00 wt-Methocel~4M 10.00 wt-1 o Aspartame 0.67 wt-Magnesium Stearate 0.33 wt-4-mQ Tablet Apomorphine Hydrochloride 2.66 wt-Mannitol 66.00 wt-z5 Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-Avicel PH102 15.00 wt-Methocel E4M 10.00 wt-Aspartame 0.67 wt-2 o Magnesium Stearate 0.33 wt-5-m~ Tablet Apomorphine Hydrochloride 3.33 wt-Mannitol 65.34 wt-Ascorbic Acid 3.33 wt-25 ' Citric Acid 2.00 wt-Avicel PH102 15.00 wt-Methocel E4M 10.00 wt-Aspartame 0.67 wt-Magnesium Stearate 0.33 wt-If desired, and in order t o facilitate absorption and thus bioavailability, the presently contemplated dosage forms can also c ontain, in addition to tabletting excipients, ~3-cyclodex trin or a 35 (3-cyclodextrin derivative such as hy droxypropyl-(3-cyclodextrin (HPBCD). Illustrative dosage forms containing HPBCD are shown in Tables II and III, below.
*Trademark ,; B
~i88~85 TABLE II
Apomorphine Hydrochloride Sublingual Tablets With Hydroxypropyl ~3-Cyclodextrin mglTab Apomorphine Hydrochloride 4.0 HPBCD 5.0 Ascorbic Acid 10.0 PEG8000 39.5 to Mannitol 39.5 Aspartame 2.0 TOTAL 100.0 TABLE III
Apomorphine Hydrochloride Sublingual Tablets With /3-Cyclodextrin mg/Tab Apomorphine Hydrochloride 5.0 2 o a-Cyclodextrin 20.0 Ascorbic Acid 5.0 Mannitol 68.g Magnesium Stearate 1.0 D&C Yellow 10 Aluminum Lake 0.1 2 5 TOTAL 100.0 The onset of nausea can be obviated or delayed by delivering apomorphine at a controlled dissolution rate so as to provide circulating serum levels and mid-30 brain tissue levels of apomorphine sufficient for an erection without inducing nausea. When apomorphine is administered at or near the relatively higher amounts of the aforementioned dosage range, the likelihood of nausea onset can be reduced by concurrent administration 35 of a ganglionic agent (inhibitor of ganglionic response) such as nicotine or lobeline sulfate. For this purpose, WO 95/28930 ~ PCTlUS95/04897 _ g _ the weight ratio of apomorphine to ganglionic agent is in the range of about 10 to about 1.
Other antiemetic agents that can be used in conjunction with apomorphine are antidopaminergic agents such as metoclopramide, and the phenothiazines, e.g., chlorpromazine, prochlorperazine, pipamazine, thiethylperazine, oxypendyl hydrochloride, and the like.
Also suitable are the serotonin (5-hydroxytryptamine or 5-HT) antagonists such as domperidone, odansetron (commercially available as the hydrochloride salt under the designation Zofran°), and the like, the histamine antagonists such as buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate (Dramamine), and the like, the parasympathetic depressants such as scopolamine, and the like, as well as other anti-emetics such as metopimazine, trimethobenzamide, benzquinamine hydrochloride, diphenidol hydrochloride, and the like.
Nicotine-containing dosage forms and domperidone-containing dosage forms are illustrated in Table IV, below.
r__..~ _._...__ _.___.~_.r.._.__ ~ , . i TABLE IV
Apomorphine Hydrochloride Sublingual Tablets Containing an Anti-Emetic Agent mg/Tab Apomorphine Hydrochloride 5.0 Ascorbic Acid 5.0 Mannitol 67.9 Magnesium Stearate 1.0 1 o Nicotine 1.0 a-Cyclodextrin 20.0 D8~C Yellow 10 Aluminum Lake 0.1 TOTAL 100.0 mg/Tab Apomorphine Hydrochloride 5.0 Ascorbic Acid 5.0 Mannitol 58.9 2 o Magnesium Stearate 1.0 Domperidone 10.0 a-Cyclodextrin 20.0 D&C Yellow 10 Aluminum Lake 0.1 TOTAL 100.0 The preferred sublingual dosage forms dissolve within a time period of at least about 2 minutes but less than about 10 minutes. More preferably, the dissolution time in water for the presently contemplated dosage forms is about 3 minutes to about 5 minutes.
The present invention is illustrated further by the following studies which were focused on two specific objectives. The first was to determine whether, relative to placebo response, patients who presented with "psychogenic" impotence (i.e., patients who were still capable of achieving erections) demonstrated improved erectile function and/or enhanced sexual desire post-dosing with sublingual apomorphine (APO). The second objective was to determine what WO 95/28930 ,~ PCTIUS95/04897 doses) of various forms of sublingual APO are effective in this group of patients for inducing an erection that is sufficient for vaginal penetration.
Participating patients were selected from among those that initially presented with the complaint of impotence. These patients underwent a thorough urological assessment by a urologist as well as an assessment by a psychiatrist. Diagnostic testing for erectile difficulties was extensive and included the following: biochemical profile, nocturnal penile tumescence (NPT) monitoring, doppler flow studies, biothesiometry, corporal calibration testing with an intracorporal injection of triple therapy and dynamic cavernosometry. These tests were used to rule out any arterial, venous or peripheral neural causality of impotence. Any patients with abnormalities in any of these three areas were excluded from entry to the trials. The inclusion/exclusion criteria for all four pilot studies are set forth in Table V, below. Patients who met all criteria were diagnosed as having impotence primarily of a psychogenic origin. If there were no known medical contraindications to the use of a dopaminergic medication they were offered entry into an APO trial.
Instructions were given regarding the protocol by the research clinician, and an informed consent was obtained. Patients were advised that they were free to withdraw from the trial at any time without penalty or prejudice. They were tested on at least three separate days at three separate doses (placebo and two active medication doses) with an interval of no less than three days between. The experimental scheme described below was used in all four pilot studies.
Patients were seated in a comfortable chair and a RIGISCANT~"'~ ambulatory tumescence monitor (Dacomed r . .....__r.___._ .. _____.t________ ., , 2 ~ 8~~85 Corp., Minneapolis, Minnesota) was placed on the patient and the computer was set in the real time monitoring mode. Blood pressure and heart rate were recorded pre-dosing with APO or placebo and at the end of the testing session. Visual analogue scales (VAS) were completed by the patient pre-dosing as well as post-dosing (at the end of the testing session). These scales reflected the patient's sense of well being, level of sedation, tranquilization, anxiousness, arousal and any changes in yawning behavior. In a single-blind fashion, apomorphine or placebo was administered to the patient sublingually. Doses of active medication varied on the formulation of the apomorphine administered (liquid or tablet). Because of the possibility of nausea and the tolerance to this effect that prior dosing conveys, the patient was given increasing doses at each testing.
However, the patient was unaware of the dose that he was receiving (single-blind). Patients were instructed not to swallow the medication, but to keep it under their tongue and allow it to be absorbed there.
Symptoms as they were volunteered were recorded by the research clinician. If the patient complained of nausea or felt unwell in any way he was asked if he wanted to abort the trial. If the trial was aborted, the patient was given Gravol 50 mg. p.o. at that time. The patient was monitored by the research clinician until these side-effects had subsided. ~He was asked to return the following week for retesting at the same dose and was instructed to begin treatment with Domperidone 10 m.g. p.o. TID the day before and morning of his next session.
Patients not experiencing nausea or any other significant adverse effects within fifteen minutes post-dosing with APO or placebo viewed segments of standardized erotic videos to provide sexual WO 95/28930 ~ ~ PCT/US95I04897 stimulation. The following sequence of videos was viewed: a ten minute erotic video, a neutral video lasting between five and ten minutes in duration and finally another ten minute erotic video. The duration of the testing session for each dose level lasted between 45 and 60 minutes. After determining. the most effective dose of apomorphine for the patient, he was then offered APO for domestic trial at that dose.
Results of Pilot Studies 1 to 4 The frequency and the magnitude of erectile responses were documented with each dose of apomorphine or placebo. Data obtained from the RIGISCANTw monitor was downloaded and each session was scanned. Erection responses were then scored for rigidity (%) and tumescence (cm.) at both the tip and base of the penis and an overall score was given that corresponded to these parameters during the viewing of both erotic and neutral video segments (see Table VI, below). A score of less than 16 indicated erectile dysfunction and a poor response to apomorphine at that dose.
Visual analogue scales (See Table IX) were compared both pre- and post-dosing, and examined for changes in feeling of well being, levels of arousal, anxiousness, sedation/tranquilization and yawning behavior. Blood pressure and heart rate were also compared pre- and post-dosing.
Effects of apomorphine that were both reported to and observed by the research clinician were grouped into two categories: Adverse Effects (i.e., flushing, diaphoresis, nausea, vomiting, changes in blood pressure or heart rate) or Primary Effects (i.e., yawning and erections).
Each pilot study was reviewed under the categories mentioned above.
__._.T _.___..._~_._.~..T...._____....~ , _ _ ~188.~85 Pilot Study #1 The initial formulation evaluated was liquid apomorphine administered via sublingual route. APO was prepared by a clinic pharmacist and dissolved in a solution of sodium metabisulfite and ethylenediamine tetraacetic acid (EDTA). The final concentration was 100 mg./ml. Patients were tested on three separate occasions at three separate doses (placebo; 10 mg.; 20 mg.) Twelve patients entered into this trial. All patients had reported erectile dysfunction greater than 1 year in duration. The age range in this group was from 38 to 60 years. One patient withdrew after placebo and another withdrew after adverse effects at the 20 mg.
dose. That left a total evaluable group of ten. All ten patients had previously received yohimbine HC1 for erectile dysfunction. Eight had failed a trial of yohimbine HC1. Of this group of eight, 6 were successful with apomorphine.
Seven (70%) were success (score of no less than 16 on both neutral and erotic video segments; Table VI) and three (30%) were categorized as failures with apomorphine. Six out of the seven successful patients continued on with a domestic trial of apomorphine at the dose that gave them the best response during testing.
Three required treatment with Domperidone the day before and morning of apomorphine usage. The range of domestic use varied from two to seven months.
Analysis of visual analogue scales pre- and post-dosing with apomorphine indicated the following.
At the end of the session patients were relaxed but not sedated. There was no evidence of arousal or anxiousness. Yawning behavior changes were evident on these scales with the incidence of yawning increasing between 15 and fifty minutes post-dosing and with each 218~38~
increase in dosing. Eac;,atient experienced between two to five yawns per ses_=ion. These changes were not evident with placebo.
The primary ef=ect of yawning was both reported by patients and observed at both 10 mg. and 20 mg. doses. No yawning was reported with placebo.
Adverse effects were reported at both dose levels. Two patients who did not experience nausea or diaphoresis were researched for similarities in their patient profiles but none were fo-.rnd. Anywhere from ten to fifteen minutes post-dosing the other eight patients developed sudden onset of various levels of nausea (and in one instance vomiting), diaphoresis, dizziness, double or blurred vision, decrease in both blood pressure and heart rate a-d pale or ashen coloring.
Side effects varied from being transient and brief to lasting as long as from 30 to 40 minutes. One patient reported a stuffy nose starting approximately 30 minutes post-dosing and lasting for approximately 10 minutes.
No adverse effects were r~ported post placebo dosing.
The foregoing Pilot Study leads to the following conclusions:
1. Apomorphin~ is effective in inducing erectile episodes without _ncreasing libido in the "psychogenically" impoter~ male.
2. Both 10 mg. and 20 mg. doses produce erectile responses.
3. Both doses produced adverse effects (nausea, vomiting, diaphoresis, etc.) that would be unacceptable to patients and their partners, however.
These effects can be cou~~eracted with the use of Domperidone.
Pilot Study #2 The first sublingual tablet formulations evaluated were 2.5 and 5 :ag. Patients were tested on T _..~ ~T_, ~ , _ __._ ZI~83$~
three separate occasions at three separate doses (placebo; 2.5 mg., 5 mg.).
A total of eight patients entered into this trial. All patients reported erectile difficulties for more that two years. The age range was from 38 to 62 years. All had failed a trial of yohimbine HC1. One patient withdrew from the trial after experiencing adverse effects at the 5 mg. dose. That left a total of seven evaluable patients.
Two (29%) were successes (score of no less than 16; Table VI) and five (71%) were failures during lab testing. The two successful patients went onto a domestic trial of apomorphine at the 2.5 mg. dose which was the most effective and did not produce adverse effects. Both patients used apomorphine at home for no less than two months with satisfactory results.
Analysis of visual analogue scales pre- and post-dosing with apomorphine indicated the same trends as with the liquid apomorphine preparation. Patients were relaxed but not sedated. No evidence of arousal or anxiousness was noted.
The primary effect of yawning was both reported by patients and observed at both 2.5 mg. and 5 mg. doses. The incidence of yawning increased between fifteen and forty minutes post-dosing. At the 2.5 mg.
dose all patients who failed testing had only one or two yawns per session. The 5 mg. dose not only produced adverse effects (nausea, diaphoresis, dizziness, blurred vision, facial flushing, drop in both heart rate and blood pressure) but also increased yawning responses to three to five times per session. The two successful patients experienced three to five yawns at both the 2.5 mg. and 5 mg. doses. These changes were not evident with placebo.
21 ~83~~
At the end of Pilot Study #2 the following conclusions were made:
1. There appears to be a correlation between the effectiveness of the dose and yawning response (poor responders experience less yawning).
2. Both 2.5 and 5 mg. doses produced erectile responses in some patients. The apparent 28%
success rate was because of lab use only (failures were not given drug to take home) and lack of available intermediate doses.
3. In some instances the 5 mg. dose can produce adverse effects (i.e., nausea, diaphoresis, etc.) that may be unacceptable to patients and their partners. These effects can be counteracted with the administration of Domperidone or nicotine (e.g., by smoking).
4. The sublingual tablets were easy to administer and dissolved within five minutes.
Pilot Study #3 Apomorphine was evaluated as an aqueous intranasal spray (1.25 mg. per puff). The first patient was an anxious, 53 year old male who had been experiencing erectile dysfunction for two years. This patient had previously failed a trial of yohimbine.
He was tested on three separate occasions at three separate doses (placebo, 2.5 mg.; 3.75 mg.) and was categorized as a failure with the score of less than sixteen on both erotic and neutral video segments. He experienced yawning with both 2.5 mg. and the 3.75 mg.
and was successful with this trial for two months until he inadvertently increased the dose. Adverse effects occurred within five minutes post-dosing (nausea and vomiting, dizziness, double and blurred vision, diaphoresis, and ashen coloring). The patient refused ,. ~ _ _.... .T ~.._~... _.~__ j _ to retry medication after this incident. He stated he did not like this formulation.
Patient No. 2 was twenty-one year old male with erectile problems of a duration of three years. He had failed a previous course of yohimbine HC1. Ten minutes post-dosing with apomorphine at 2.5 mg. he experienced yawing for a total of five yawns, and then experienced immediately major hemodynamic adverse effects. These included pale and ashen coloring, diaphoresis, nausea and vomiting, blurred vision, hypotension with a blood pressure of 70/50. Twenty minutes post adverse effect, vital signs were stable.
The patient was feeling well, and coloring was good.
This patient was then dropped from further testing.
Although the intranasal administration was effective in eliciting an erection, further testing of this intranasal formulation of apomorphine was discontinued because of possible overdose and increased side effects The foregoing experience illustrates the need for reliable and relatively safer dosage forms, however.
Pilot Study #4 New sublingual tablet formulations of apomorphine at 3, 4 and 5 mg. doses (Table I, above) were evaluated. Patients were tested on at least three separate occasions on at least three separate doses (placebo; 3 mg.; and 4 mg.). A 5 mg. sublingual dose was also tested in some patients. The results of this study are summarized in Tables VII and VIII A-C, below.
To date, twelve patients have been completely evaluated on this formulation. All patients reported erectile dysfunction for more than two years. The patients' age range was thirty-nine to sixty-six years.
Three patients had been successful with yohimbine HC1 in the past, and two had previously not tried this 883~~
WO 95/28930 PC'T/US95/04897 compound. Seven patients of this group of twelve had previously failed a trial of yohimbine HC1. Of this latter group of seven, four were successfully treated with apomorphine.
Eight (67%) have been successful with apomorphine to date. Four (33%) were failures with apomorphine. Both 3 mg. and 4 mg. doses produced erectile responses. Several patients went on to a trial of the 5 mg. sublingual dose which did not appear to be more effective than the relatively lesser doses in terms of erectile response. All eight of the successful patients continued on with the domestic use for a time period of one to four months. All patients reported good erectile activity and no side effects.
Analysis of visual analogue scales, both pre- and post-dosing with apomorphine, again indicated that the patients were relaxed but not sedated, and did not have feelings of arousal or anxiousness post-dosing.
The new formulations tested (3 mg.; 4 mg.; and 5 mg.) were devoid of adverse effects. The patients felt well post testing, and did not report or demonstrate any adverse effects that had traditionally been seen with the administration of previous apomorphine liquid and intranasal preparations (Pilot Studies No. 1 and No. 3).
The primary effect of yawning was still reported and observed at all doses, but the number and frequency of yawns was small (one or two).
The foregoing pilot study shows that 3-mg., 4-mg. and 5-mg. apomorphine doses are effective in inducing penile erections, and also that there are no serious adverse effects with these preparations.
Domestic use of these preparations was well accepted by patients and their partners. They were content with the convenience of dosing approximately fifteen minutes prior to sexual activity. All patients have stated that ..r _...____. _ .._..___ _.~...__. ..r ~~88~85 this was more acceptable than dealing with dosing on a routine basis.
TABLE V
InclusionlExclusion Criteria INCLUSION CRITERIA:
1. Age 18-66 years.
2. NPT circumference increase of 1.5 cm or more on one night and >70% rigidity.
3. ICI circumference increase of 1.5 cm or more and >70%
rigidity.
EXCLUS ION CRITERIA:
l0 1. Currently severe or life threatening systemic disease.
2. Clinically significant ECG abnormalities.
3. Personal or first degree family history of epilepsy.
4. Abnormal: Hepatic/renal function Hematology 5. Low: pre-trial testosterone Low or High: LH
High: Prolactin 6. Hypertension requiring treatment.
The apomorphine is administered preferably about 15 to about 20 minutes prior to sexual activity.
Apomorphine can be represented by the formula i Ha \ N
HO ~ \
OH
and exists in a free base form or as an acid addition salt. For the purposes of the present invention apomorphine hydrochloride is preferred; however, other pharmacologically acceptable moieties thereof can be utilized as well. The term "apomorphine" as used herein includes the free base form of this compound as well as the pharmacologically acceptable acid addition salts thereof. In addition to the hydrochloride salt, other acceptable acid addition salts are the hydrobromide, the hydroiodide, the bisulfate, the phosphate, the acid phosphate, the lactate, the citrate, the tartarate, the salicylate, the succinate, the maleate, the gluconate, and the like.
Illustrative preferred sublingual dosage forms are set forth in Table I, below.
1W0 95/28930 2 ~ 8 8 3 8 5 P~~S95/04897 TABLE I
150-Milligram Apomorphine Hydrochloride Sublingual Tablets 3-m Tc~ ablet Apomorphine Hydrochloride 2.00 wt-Mannitol 66.67 wt-Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-Avicel*PH102 15.00 wt-Methocel~4M 10.00 wt-1 o Aspartame 0.67 wt-Magnesium Stearate 0.33 wt-4-mQ Tablet Apomorphine Hydrochloride 2.66 wt-Mannitol 66.00 wt-z5 Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-Avicel PH102 15.00 wt-Methocel E4M 10.00 wt-Aspartame 0.67 wt-2 o Magnesium Stearate 0.33 wt-5-m~ Tablet Apomorphine Hydrochloride 3.33 wt-Mannitol 65.34 wt-Ascorbic Acid 3.33 wt-25 ' Citric Acid 2.00 wt-Avicel PH102 15.00 wt-Methocel E4M 10.00 wt-Aspartame 0.67 wt-Magnesium Stearate 0.33 wt-If desired, and in order t o facilitate absorption and thus bioavailability, the presently contemplated dosage forms can also c ontain, in addition to tabletting excipients, ~3-cyclodex trin or a 35 (3-cyclodextrin derivative such as hy droxypropyl-(3-cyclodextrin (HPBCD). Illustrative dosage forms containing HPBCD are shown in Tables II and III, below.
*Trademark ,; B
~i88~85 TABLE II
Apomorphine Hydrochloride Sublingual Tablets With Hydroxypropyl ~3-Cyclodextrin mglTab Apomorphine Hydrochloride 4.0 HPBCD 5.0 Ascorbic Acid 10.0 PEG8000 39.5 to Mannitol 39.5 Aspartame 2.0 TOTAL 100.0 TABLE III
Apomorphine Hydrochloride Sublingual Tablets With /3-Cyclodextrin mg/Tab Apomorphine Hydrochloride 5.0 2 o a-Cyclodextrin 20.0 Ascorbic Acid 5.0 Mannitol 68.g Magnesium Stearate 1.0 D&C Yellow 10 Aluminum Lake 0.1 2 5 TOTAL 100.0 The onset of nausea can be obviated or delayed by delivering apomorphine at a controlled dissolution rate so as to provide circulating serum levels and mid-30 brain tissue levels of apomorphine sufficient for an erection without inducing nausea. When apomorphine is administered at or near the relatively higher amounts of the aforementioned dosage range, the likelihood of nausea onset can be reduced by concurrent administration 35 of a ganglionic agent (inhibitor of ganglionic response) such as nicotine or lobeline sulfate. For this purpose, WO 95/28930 ~ PCTlUS95/04897 _ g _ the weight ratio of apomorphine to ganglionic agent is in the range of about 10 to about 1.
Other antiemetic agents that can be used in conjunction with apomorphine are antidopaminergic agents such as metoclopramide, and the phenothiazines, e.g., chlorpromazine, prochlorperazine, pipamazine, thiethylperazine, oxypendyl hydrochloride, and the like.
Also suitable are the serotonin (5-hydroxytryptamine or 5-HT) antagonists such as domperidone, odansetron (commercially available as the hydrochloride salt under the designation Zofran°), and the like, the histamine antagonists such as buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate (Dramamine), and the like, the parasympathetic depressants such as scopolamine, and the like, as well as other anti-emetics such as metopimazine, trimethobenzamide, benzquinamine hydrochloride, diphenidol hydrochloride, and the like.
Nicotine-containing dosage forms and domperidone-containing dosage forms are illustrated in Table IV, below.
r__..~ _._...__ _.___.~_.r.._.__ ~ , . i TABLE IV
Apomorphine Hydrochloride Sublingual Tablets Containing an Anti-Emetic Agent mg/Tab Apomorphine Hydrochloride 5.0 Ascorbic Acid 5.0 Mannitol 67.9 Magnesium Stearate 1.0 1 o Nicotine 1.0 a-Cyclodextrin 20.0 D8~C Yellow 10 Aluminum Lake 0.1 TOTAL 100.0 mg/Tab Apomorphine Hydrochloride 5.0 Ascorbic Acid 5.0 Mannitol 58.9 2 o Magnesium Stearate 1.0 Domperidone 10.0 a-Cyclodextrin 20.0 D&C Yellow 10 Aluminum Lake 0.1 TOTAL 100.0 The preferred sublingual dosage forms dissolve within a time period of at least about 2 minutes but less than about 10 minutes. More preferably, the dissolution time in water for the presently contemplated dosage forms is about 3 minutes to about 5 minutes.
The present invention is illustrated further by the following studies which were focused on two specific objectives. The first was to determine whether, relative to placebo response, patients who presented with "psychogenic" impotence (i.e., patients who were still capable of achieving erections) demonstrated improved erectile function and/or enhanced sexual desire post-dosing with sublingual apomorphine (APO). The second objective was to determine what WO 95/28930 ,~ PCTIUS95/04897 doses) of various forms of sublingual APO are effective in this group of patients for inducing an erection that is sufficient for vaginal penetration.
Participating patients were selected from among those that initially presented with the complaint of impotence. These patients underwent a thorough urological assessment by a urologist as well as an assessment by a psychiatrist. Diagnostic testing for erectile difficulties was extensive and included the following: biochemical profile, nocturnal penile tumescence (NPT) monitoring, doppler flow studies, biothesiometry, corporal calibration testing with an intracorporal injection of triple therapy and dynamic cavernosometry. These tests were used to rule out any arterial, venous or peripheral neural causality of impotence. Any patients with abnormalities in any of these three areas were excluded from entry to the trials. The inclusion/exclusion criteria for all four pilot studies are set forth in Table V, below. Patients who met all criteria were diagnosed as having impotence primarily of a psychogenic origin. If there were no known medical contraindications to the use of a dopaminergic medication they were offered entry into an APO trial.
Instructions were given regarding the protocol by the research clinician, and an informed consent was obtained. Patients were advised that they were free to withdraw from the trial at any time without penalty or prejudice. They were tested on at least three separate days at three separate doses (placebo and two active medication doses) with an interval of no less than three days between. The experimental scheme described below was used in all four pilot studies.
Patients were seated in a comfortable chair and a RIGISCANT~"'~ ambulatory tumescence monitor (Dacomed r . .....__r.___._ .. _____.t________ ., , 2 ~ 8~~85 Corp., Minneapolis, Minnesota) was placed on the patient and the computer was set in the real time monitoring mode. Blood pressure and heart rate were recorded pre-dosing with APO or placebo and at the end of the testing session. Visual analogue scales (VAS) were completed by the patient pre-dosing as well as post-dosing (at the end of the testing session). These scales reflected the patient's sense of well being, level of sedation, tranquilization, anxiousness, arousal and any changes in yawning behavior. In a single-blind fashion, apomorphine or placebo was administered to the patient sublingually. Doses of active medication varied on the formulation of the apomorphine administered (liquid or tablet). Because of the possibility of nausea and the tolerance to this effect that prior dosing conveys, the patient was given increasing doses at each testing.
However, the patient was unaware of the dose that he was receiving (single-blind). Patients were instructed not to swallow the medication, but to keep it under their tongue and allow it to be absorbed there.
Symptoms as they were volunteered were recorded by the research clinician. If the patient complained of nausea or felt unwell in any way he was asked if he wanted to abort the trial. If the trial was aborted, the patient was given Gravol 50 mg. p.o. at that time. The patient was monitored by the research clinician until these side-effects had subsided. ~He was asked to return the following week for retesting at the same dose and was instructed to begin treatment with Domperidone 10 m.g. p.o. TID the day before and morning of his next session.
Patients not experiencing nausea or any other significant adverse effects within fifteen minutes post-dosing with APO or placebo viewed segments of standardized erotic videos to provide sexual WO 95/28930 ~ ~ PCT/US95I04897 stimulation. The following sequence of videos was viewed: a ten minute erotic video, a neutral video lasting between five and ten minutes in duration and finally another ten minute erotic video. The duration of the testing session for each dose level lasted between 45 and 60 minutes. After determining. the most effective dose of apomorphine for the patient, he was then offered APO for domestic trial at that dose.
Results of Pilot Studies 1 to 4 The frequency and the magnitude of erectile responses were documented with each dose of apomorphine or placebo. Data obtained from the RIGISCANTw monitor was downloaded and each session was scanned. Erection responses were then scored for rigidity (%) and tumescence (cm.) at both the tip and base of the penis and an overall score was given that corresponded to these parameters during the viewing of both erotic and neutral video segments (see Table VI, below). A score of less than 16 indicated erectile dysfunction and a poor response to apomorphine at that dose.
Visual analogue scales (See Table IX) were compared both pre- and post-dosing, and examined for changes in feeling of well being, levels of arousal, anxiousness, sedation/tranquilization and yawning behavior. Blood pressure and heart rate were also compared pre- and post-dosing.
Effects of apomorphine that were both reported to and observed by the research clinician were grouped into two categories: Adverse Effects (i.e., flushing, diaphoresis, nausea, vomiting, changes in blood pressure or heart rate) or Primary Effects (i.e., yawning and erections).
Each pilot study was reviewed under the categories mentioned above.
__._.T _.___..._~_._.~..T...._____....~ , _ _ ~188.~85 Pilot Study #1 The initial formulation evaluated was liquid apomorphine administered via sublingual route. APO was prepared by a clinic pharmacist and dissolved in a solution of sodium metabisulfite and ethylenediamine tetraacetic acid (EDTA). The final concentration was 100 mg./ml. Patients were tested on three separate occasions at three separate doses (placebo; 10 mg.; 20 mg.) Twelve patients entered into this trial. All patients had reported erectile dysfunction greater than 1 year in duration. The age range in this group was from 38 to 60 years. One patient withdrew after placebo and another withdrew after adverse effects at the 20 mg.
dose. That left a total evaluable group of ten. All ten patients had previously received yohimbine HC1 for erectile dysfunction. Eight had failed a trial of yohimbine HC1. Of this group of eight, 6 were successful with apomorphine.
Seven (70%) were success (score of no less than 16 on both neutral and erotic video segments; Table VI) and three (30%) were categorized as failures with apomorphine. Six out of the seven successful patients continued on with a domestic trial of apomorphine at the dose that gave them the best response during testing.
Three required treatment with Domperidone the day before and morning of apomorphine usage. The range of domestic use varied from two to seven months.
Analysis of visual analogue scales pre- and post-dosing with apomorphine indicated the following.
At the end of the session patients were relaxed but not sedated. There was no evidence of arousal or anxiousness. Yawning behavior changes were evident on these scales with the incidence of yawning increasing between 15 and fifty minutes post-dosing and with each 218~38~
increase in dosing. Eac;,atient experienced between two to five yawns per ses_=ion. These changes were not evident with placebo.
The primary ef=ect of yawning was both reported by patients and observed at both 10 mg. and 20 mg. doses. No yawning was reported with placebo.
Adverse effects were reported at both dose levels. Two patients who did not experience nausea or diaphoresis were researched for similarities in their patient profiles but none were fo-.rnd. Anywhere from ten to fifteen minutes post-dosing the other eight patients developed sudden onset of various levels of nausea (and in one instance vomiting), diaphoresis, dizziness, double or blurred vision, decrease in both blood pressure and heart rate a-d pale or ashen coloring.
Side effects varied from being transient and brief to lasting as long as from 30 to 40 minutes. One patient reported a stuffy nose starting approximately 30 minutes post-dosing and lasting for approximately 10 minutes.
No adverse effects were r~ported post placebo dosing.
The foregoing Pilot Study leads to the following conclusions:
1. Apomorphin~ is effective in inducing erectile episodes without _ncreasing libido in the "psychogenically" impoter~ male.
2. Both 10 mg. and 20 mg. doses produce erectile responses.
3. Both doses produced adverse effects (nausea, vomiting, diaphoresis, etc.) that would be unacceptable to patients and their partners, however.
These effects can be cou~~eracted with the use of Domperidone.
Pilot Study #2 The first sublingual tablet formulations evaluated were 2.5 and 5 :ag. Patients were tested on T _..~ ~T_, ~ , _ __._ ZI~83$~
three separate occasions at three separate doses (placebo; 2.5 mg., 5 mg.).
A total of eight patients entered into this trial. All patients reported erectile difficulties for more that two years. The age range was from 38 to 62 years. All had failed a trial of yohimbine HC1. One patient withdrew from the trial after experiencing adverse effects at the 5 mg. dose. That left a total of seven evaluable patients.
Two (29%) were successes (score of no less than 16; Table VI) and five (71%) were failures during lab testing. The two successful patients went onto a domestic trial of apomorphine at the 2.5 mg. dose which was the most effective and did not produce adverse effects. Both patients used apomorphine at home for no less than two months with satisfactory results.
Analysis of visual analogue scales pre- and post-dosing with apomorphine indicated the same trends as with the liquid apomorphine preparation. Patients were relaxed but not sedated. No evidence of arousal or anxiousness was noted.
The primary effect of yawning was both reported by patients and observed at both 2.5 mg. and 5 mg. doses. The incidence of yawning increased between fifteen and forty minutes post-dosing. At the 2.5 mg.
dose all patients who failed testing had only one or two yawns per session. The 5 mg. dose not only produced adverse effects (nausea, diaphoresis, dizziness, blurred vision, facial flushing, drop in both heart rate and blood pressure) but also increased yawning responses to three to five times per session. The two successful patients experienced three to five yawns at both the 2.5 mg. and 5 mg. doses. These changes were not evident with placebo.
21 ~83~~
At the end of Pilot Study #2 the following conclusions were made:
1. There appears to be a correlation between the effectiveness of the dose and yawning response (poor responders experience less yawning).
2. Both 2.5 and 5 mg. doses produced erectile responses in some patients. The apparent 28%
success rate was because of lab use only (failures were not given drug to take home) and lack of available intermediate doses.
3. In some instances the 5 mg. dose can produce adverse effects (i.e., nausea, diaphoresis, etc.) that may be unacceptable to patients and their partners. These effects can be counteracted with the administration of Domperidone or nicotine (e.g., by smoking).
4. The sublingual tablets were easy to administer and dissolved within five minutes.
Pilot Study #3 Apomorphine was evaluated as an aqueous intranasal spray (1.25 mg. per puff). The first patient was an anxious, 53 year old male who had been experiencing erectile dysfunction for two years. This patient had previously failed a trial of yohimbine.
He was tested on three separate occasions at three separate doses (placebo, 2.5 mg.; 3.75 mg.) and was categorized as a failure with the score of less than sixteen on both erotic and neutral video segments. He experienced yawning with both 2.5 mg. and the 3.75 mg.
and was successful with this trial for two months until he inadvertently increased the dose. Adverse effects occurred within five minutes post-dosing (nausea and vomiting, dizziness, double and blurred vision, diaphoresis, and ashen coloring). The patient refused ,. ~ _ _.... .T ~.._~... _.~__ j _ to retry medication after this incident. He stated he did not like this formulation.
Patient No. 2 was twenty-one year old male with erectile problems of a duration of three years. He had failed a previous course of yohimbine HC1. Ten minutes post-dosing with apomorphine at 2.5 mg. he experienced yawing for a total of five yawns, and then experienced immediately major hemodynamic adverse effects. These included pale and ashen coloring, diaphoresis, nausea and vomiting, blurred vision, hypotension with a blood pressure of 70/50. Twenty minutes post adverse effect, vital signs were stable.
The patient was feeling well, and coloring was good.
This patient was then dropped from further testing.
Although the intranasal administration was effective in eliciting an erection, further testing of this intranasal formulation of apomorphine was discontinued because of possible overdose and increased side effects The foregoing experience illustrates the need for reliable and relatively safer dosage forms, however.
Pilot Study #4 New sublingual tablet formulations of apomorphine at 3, 4 and 5 mg. doses (Table I, above) were evaluated. Patients were tested on at least three separate occasions on at least three separate doses (placebo; 3 mg.; and 4 mg.). A 5 mg. sublingual dose was also tested in some patients. The results of this study are summarized in Tables VII and VIII A-C, below.
To date, twelve patients have been completely evaluated on this formulation. All patients reported erectile dysfunction for more than two years. The patients' age range was thirty-nine to sixty-six years.
Three patients had been successful with yohimbine HC1 in the past, and two had previously not tried this 883~~
WO 95/28930 PC'T/US95/04897 compound. Seven patients of this group of twelve had previously failed a trial of yohimbine HC1. Of this latter group of seven, four were successfully treated with apomorphine.
Eight (67%) have been successful with apomorphine to date. Four (33%) were failures with apomorphine. Both 3 mg. and 4 mg. doses produced erectile responses. Several patients went on to a trial of the 5 mg. sublingual dose which did not appear to be more effective than the relatively lesser doses in terms of erectile response. All eight of the successful patients continued on with the domestic use for a time period of one to four months. All patients reported good erectile activity and no side effects.
Analysis of visual analogue scales, both pre- and post-dosing with apomorphine, again indicated that the patients were relaxed but not sedated, and did not have feelings of arousal or anxiousness post-dosing.
The new formulations tested (3 mg.; 4 mg.; and 5 mg.) were devoid of adverse effects. The patients felt well post testing, and did not report or demonstrate any adverse effects that had traditionally been seen with the administration of previous apomorphine liquid and intranasal preparations (Pilot Studies No. 1 and No. 3).
The primary effect of yawning was still reported and observed at all doses, but the number and frequency of yawns was small (one or two).
The foregoing pilot study shows that 3-mg., 4-mg. and 5-mg. apomorphine doses are effective in inducing penile erections, and also that there are no serious adverse effects with these preparations.
Domestic use of these preparations was well accepted by patients and their partners. They were content with the convenience of dosing approximately fifteen minutes prior to sexual activity. All patients have stated that ..r _...____. _ .._..___ _.~...__. ..r ~~88~85 this was more acceptable than dealing with dosing on a routine basis.
TABLE V
InclusionlExclusion Criteria INCLUSION CRITERIA:
1. Age 18-66 years.
2. NPT circumference increase of 1.5 cm or more on one night and >70% rigidity.
3. ICI circumference increase of 1.5 cm or more and >70%
rigidity.
EXCLUS ION CRITERIA:
l0 1. Currently severe or life threatening systemic disease.
2. Clinically significant ECG abnormalities.
3. Personal or first degree family history of epilepsy.
4. Abnormal: Hepatic/renal function Hematology 5. Low: pre-trial testosterone Low or High: LH
High: Prolactin 6. Hypertension requiring treatment.
7. History of depression requiring treatment with antidepressants, ECT, or hospitalization.
8. Symptomatic ischemic heart disease/or MI
within the last three months.
within the last three months.
9. Diabetes.
10. Failure to obtain informed consent.
2 0 11. Legal cases.
12. Unable or unwilling to comply with protocol.
13. Drinks more than (on average) 45 units alcohol per week/or uses illicit drugs.
14. History of syncope.
15. Prohibited Drugs: sympathetic or parasympathetic types drugs, Beta blockers, Vasodilators, psychotropic medications, tranquilizers, thiazides, Captopril, Verapmil, Furosemide, Spironolactone, Metochlopramide, Cimetidine or other drugs which are likely to influence erectile function.
- ~0 -TABLE VI
Response to Erotic Videotape 1. Maximum increase in penile circumference Circumference (cms.) Score 0 - <0.5 cm. p 0.5-<1.Ocm. 1 1.0 - <1.5 cm. 2 1.5 - <2.0 cm. 3 l0 2.0 - <2.5 cm. lasts <1 min. 4 2.5 or more lasts <1 min. 5 2.0 - <2.5 cm. lasts at least 1 min. 6 2.5 or more lasts at least 1 min. 7 3.0 or more lasts at (east 5 min. 8 3.0 or more lasts at least 10 min.9 Score A. Maximum increase in penile tip circumference B. Maximum increase in penile basal circumference 2. Maximum penile rigidity 2 o Rigidity (/~ Score 0-<10 0 10 - <20 1 - <30 2 - <40 3 2 5 40 - <50 4 50 - <60 5 60 - <70 6 70 - <80 7 80 - <90 8 3 0 90 - 100 g Score C. Maximum penile tip rigidity D. Maximum penile basal rigidity 3. Total score (A, B, C 8~ D) A score of less than 16 indicates erectile dysfunction i _.._T_ _......._. _.._.._.._ . _. _.._~.._..~.._.__ ~_.~ . T
ziss~ss 3 d d 'W. ~ 0~f~'vT00 r O O (DM O N 1n (DN ~ 00N M N COf~ ~ t~
v Z
o, ~ d Q U o V = ~ # COfWT C~0r O O COM O N tn v v v v v v ~~..v v v ~ ' w a d_ C d' W M r N ~ ~ r~-~ M ~ OD~' CO
N N N N
M
a ~
t ~ _ M In(O 0000_ tnN 00r r p V O
v v ~ ~ v v v ~ v v ~ C
.
.
11J d e~'. a ...
N ~ . c . p y ~ d 1~!~tn1~ (D1~Cfr r (pM r p N r r N r N
Z O
47 >
' H -, o .~
~
c'tf(D 00ODO LnN ~ e= r O E
~
v v v v .
~
M LLIN ~ N O 0000CON ~f'M (D 1~ p .N N N r r r M r N p t N
O
Q ~ N ~ ~ ~ r InO ~ O O Ln M
O
LiJ Z N "
'a p N
p O
J ;t o io io V r N (fl~ r 'sTO ODN M M f~c gyp : o .
~ ~"
irM r r N r r N r ..
O .
p N
W ~ O
N
N
t O
O
_ p t a ~c o tI~M ~ t1~ ~ ~ N N tn w ODO r c~jODO O COM O 00 M C
~DV v o0 v oDV o O 0 ~ 1~t N
... V V ~ ...
r N M ~t LnCOf~0007O r N H
O O O O O O O O O r-r r C N
~
= V ~ 'C ~T~ ~ ~1'~ ttst ~fG~ __ .~
N
O
o a O
.
The data of Pilot Study #4 were analyzed in two ways. First, mean erectile function was compared across placebo, 3 mg and 4 mg doses under two stimulus backgrounds, erotic and neutral. Next erectile function scores were dichotomized, with values less than sixteen ' considered to reflect erectile insufficiency.
A. Mean Erectile Function Table VIII A shows means and standard errors for all three treatments under both backgrounds, erotic and neutral. Means were compared using a restricted maximum likelihood generalized linear model containing two main effects, treatment and stimulus, and the treatment by stimulus interaction. An appropriate variance-covariance structure was established for the underlying statistical model using Akaike's criterion. Table VIII
B presents the statistical results for the main effects of treatment and of stimulus, for the treatment by stimulus interaction, and for orthogonal contrasts within the erotic and neutral conditions. It can be seen that the treatment main effect (i.e., general difference across treatment conditions without regard to stimulus background) is statistically significant; that the main effect of stimulus (i.e., general difference across stimulus backgrounds without regard to treatment) is statistically significant; and that the treatment by stimulus interaction is not statistically significant.
These findings imply that active treatment is more effective than placebo and that this finding, although stronger when using an erotic stimulus, is true regardless of stimulus background (see FIGURE 1). The orthogonal (statistically independent) contrasts confirm that active treatment is superior at a statistically significant level under both erotic and neutral conditions, but also indicate that the difference between the 3 mg and 4 mg dose does not exceed that _d __. _...._ __.T._. . . _~ . . r expec~~d by chance for the number of patients (12) used in th_s study.
B. P=_=cent Successful Erectile Function __GURE 2 and Table VIII C show that the stati_=~ically significant superiority of active over placebo treatment, regardless of stimulus background, is maintained when the erectile function scores are class=ied to reflect success (score at least 16) or failu=~ (score less than 16).
TABLE VIII A
Mean and Percent Successful Erectile Function Stimulus Treatment N Mean (SE) Percent (SE) Erotic Placebo 12 14.08 (2.69)33.33 (13.61) 3 mg 12 18.75 (2.5166.67 ( ) 13.61 ) 4 mg 12 19.83 (2.67)66.67 (13.61 ) 2 0 Neutral Placebo 12 6.50 (2.45)16.67 (10.76) 3 mg 12 11.83 (2.68)50.00 (14.43) 4 mg 12 13.50 (2.61)50.00 (14.43) Note: Mean (SE) from SAS PROC UNIVARIATE. Percent (SE) from SAS PROC CATMOD
WO 95/28930 2 ~ 8 g ~ 8 J PCT/US95/04897 TABLE VIII B
Anova for Mean Erectile Function EFFECT DF F P-value Treatment 2.6611.560.0000 Stimulus 1.6637.140.0000 Treatment by Stimulus 2.660.10 0.9046 Contrasts Erotic: Placebo vs. Treatment 1.669.30 0.0033 Erotic: 3 mg vs. 4 mg 1.660.30 0.5849 Neutral: Placebo vs. Treatment 1.6613.030.0006 Neutral: 3 mg vs. 4 mg 1.660.71 0.4014 Note: Restricted maximum likelihood analysis performed using SAS PROC
MIXED.
TABLE VIII C
Logistic Regression for Percent Successful Erectile Function EFFECT DF X2 P-value Treatment 2 15.360.0005 Stimulus 1 5.14 0.0233 Treatment by Stimulus 2 0.00 1.0000 Contrasts Erotic: Placebo vs. Treatment 1 9.60 0.0019 Erotic: 3 mg vs. 4 mg 1 0.00 1.0000 3 0 Neutral: Placebo vs. Treatment 1 9.60 0.0019 Neutral: 3 mg vs. 4 mg 1 0.00 1.0000 Note: Analysis performed using .
SAS PROC CATMOD
~. _ . .._. _..._. _.____._ __..... _....... _._.._T , , TABLE IX
Visual Analogue Scale (VAS) (to be completed by the patient) Please mark each line clearly at the point which indicates how you are feeling right now.
Each line represents the full range of each feeling. (There are no right or wrong answers) Score (mm) 1. Alert Drowsy 2. Calm Excited 3. Yawning Not Yawning 4. Fuzzy Clear Headed 5. Well Coordinated Clumsy 6. Tired Energetic 7. Contented Disconnected 8. Troubled Tranquil 9. Mentally slow Quick Wetted 10. Tense Relaxed 11. Attentive Dreamy 2 0 12. Stomach Upset Feeling Well 13. Anxious Carefree (measure from left to right) Dose Evaluation Studv Clinical response to sublingual administration of apomorphine was evaluated utilizing a group of 60 non-vasculogenic impotent patients. Each patient had a history of erectile dysfunction for at least 3 months, normal biothesiometry response, and normal cavernosometry results.
The patients were divided into seven groups.
Each group received a predetermined dosage of apomorphine for 20 days in the form of apomorphine hydrochloride tablets 20 minutes prior to intercourse.
Seven different dosages were evaluated - 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg and 10 mg. The tablet constituents were those shown in Table I, above.
Assessment of response was made on the basis of the PC"T/US95/04897 patient's report of his experience. A response was deemed positive when the patient experienced an erection sufficiently rigid to effect penetration. Side effects such as nausea and/or vomiting, if present, were noted as well.
The results of this study are compiled in Table X, below.
TABLE X
1 o Results of Dose Evaluation Study Positive No. of Dosage, Responses Nausea Vomiting Patients mg No. % No. % No.
From the foregoing Table it can be seen that at a 4-mg dosage 40 percent of patients had a positive response, at a 5-mg dosage 50 percent of patients had a positive response, at 6-mg, 7-mg, and 8-mg dosages 70 percent of patients had a positive response and at a 10-mg dosage 80 percent of patients had a positive response. :iowever, the incidence of side effects increased as well as the dosage was increased.
The aforesaid apomorphine dosage forms are also well suited for diagnosing male human patients suffering from male erectile dysfunction. For diagnostic purposes, at least about 3 milligrams of apomorphine are administered sublingually to the patient 1 ~__... ~..._.. . . . ~_.__... T ~ .
and the patient is exposed to a visual erotic stimulus, e.g., an erotic videotape, while the patient's response thereto is monitored. If deemed desirable for diagnostic purposes, up to about 10 milligrams of apomorphine can be administered to the patient.
In particular, the patient's maximum increase in penile circumference (preferably tip as well as basal) is determined and the patient's maximum penile rigidity (preferably tip as well as basal) is determined. The determined circumferential increase and rigidity values are then compared against a predetermined base value. Equivalent methods of determining tumescence and rigidity can also be utilized.
The foregoing discussion and the reported studies are intended as illustrative of the present invention and are not to be taken as limiting. Still other variants within the spirit and scope of this invention are possible and will readily present themselves to those skilled in the art.
2 0 11. Legal cases.
12. Unable or unwilling to comply with protocol.
13. Drinks more than (on average) 45 units alcohol per week/or uses illicit drugs.
14. History of syncope.
15. Prohibited Drugs: sympathetic or parasympathetic types drugs, Beta blockers, Vasodilators, psychotropic medications, tranquilizers, thiazides, Captopril, Verapmil, Furosemide, Spironolactone, Metochlopramide, Cimetidine or other drugs which are likely to influence erectile function.
- ~0 -TABLE VI
Response to Erotic Videotape 1. Maximum increase in penile circumference Circumference (cms.) Score 0 - <0.5 cm. p 0.5-<1.Ocm. 1 1.0 - <1.5 cm. 2 1.5 - <2.0 cm. 3 l0 2.0 - <2.5 cm. lasts <1 min. 4 2.5 or more lasts <1 min. 5 2.0 - <2.5 cm. lasts at least 1 min. 6 2.5 or more lasts at least 1 min. 7 3.0 or more lasts at (east 5 min. 8 3.0 or more lasts at least 10 min.9 Score A. Maximum increase in penile tip circumference B. Maximum increase in penile basal circumference 2. Maximum penile rigidity 2 o Rigidity (/~ Score 0-<10 0 10 - <20 1 - <30 2 - <40 3 2 5 40 - <50 4 50 - <60 5 60 - <70 6 70 - <80 7 80 - <90 8 3 0 90 - 100 g Score C. Maximum penile tip rigidity D. Maximum penile basal rigidity 3. Total score (A, B, C 8~ D) A score of less than 16 indicates erectile dysfunction i _.._T_ _......._. _.._.._.._ . _. _.._~.._..~.._.__ ~_.~ . T
ziss~ss 3 d d 'W. ~ 0~f~'vT00 r O O (DM O N 1n (DN ~ 00N M N COf~ ~ t~
v Z
o, ~ d Q U o V = ~ # COfWT C~0r O O COM O N tn v v v v v v ~~..v v v ~ ' w a d_ C d' W M r N ~ ~ r~-~ M ~ OD~' CO
N N N N
M
a ~
t ~ _ M In(O 0000_ tnN 00r r p V O
v v ~ ~ v v v ~ v v ~ C
.
.
11J d e~'. a ...
N ~ . c . p y ~ d 1~!~tn1~ (D1~Cfr r (pM r p N r r N r N
Z O
47 >
' H -, o .~
~
c'tf(D 00ODO LnN ~ e= r O E
~
v v v v .
~
M LLIN ~ N O 0000CON ~f'M (D 1~ p .N N N r r r M r N p t N
O
Q ~ N ~ ~ ~ r InO ~ O O Ln M
O
LiJ Z N "
'a p N
p O
J ;t o io io V r N (fl~ r 'sTO ODN M M f~c gyp : o .
~ ~"
irM r r N r r N r ..
O .
p N
W ~ O
N
N
t O
O
_ p t a ~c o tI~M ~ t1~ ~ ~ N N tn w ODO r c~jODO O COM O 00 M C
~DV v o0 v oDV o O 0 ~ 1~t N
... V V ~ ...
r N M ~t LnCOf~0007O r N H
O O O O O O O O O r-r r C N
~
= V ~ 'C ~T~ ~ ~1'~ ttst ~fG~ __ .~
N
O
o a O
.
The data of Pilot Study #4 were analyzed in two ways. First, mean erectile function was compared across placebo, 3 mg and 4 mg doses under two stimulus backgrounds, erotic and neutral. Next erectile function scores were dichotomized, with values less than sixteen ' considered to reflect erectile insufficiency.
A. Mean Erectile Function Table VIII A shows means and standard errors for all three treatments under both backgrounds, erotic and neutral. Means were compared using a restricted maximum likelihood generalized linear model containing two main effects, treatment and stimulus, and the treatment by stimulus interaction. An appropriate variance-covariance structure was established for the underlying statistical model using Akaike's criterion. Table VIII
B presents the statistical results for the main effects of treatment and of stimulus, for the treatment by stimulus interaction, and for orthogonal contrasts within the erotic and neutral conditions. It can be seen that the treatment main effect (i.e., general difference across treatment conditions without regard to stimulus background) is statistically significant; that the main effect of stimulus (i.e., general difference across stimulus backgrounds without regard to treatment) is statistically significant; and that the treatment by stimulus interaction is not statistically significant.
These findings imply that active treatment is more effective than placebo and that this finding, although stronger when using an erotic stimulus, is true regardless of stimulus background (see FIGURE 1). The orthogonal (statistically independent) contrasts confirm that active treatment is superior at a statistically significant level under both erotic and neutral conditions, but also indicate that the difference between the 3 mg and 4 mg dose does not exceed that _d __. _...._ __.T._. . . _~ . . r expec~~d by chance for the number of patients (12) used in th_s study.
B. P=_=cent Successful Erectile Function __GURE 2 and Table VIII C show that the stati_=~ically significant superiority of active over placebo treatment, regardless of stimulus background, is maintained when the erectile function scores are class=ied to reflect success (score at least 16) or failu=~ (score less than 16).
TABLE VIII A
Mean and Percent Successful Erectile Function Stimulus Treatment N Mean (SE) Percent (SE) Erotic Placebo 12 14.08 (2.69)33.33 (13.61) 3 mg 12 18.75 (2.5166.67 ( ) 13.61 ) 4 mg 12 19.83 (2.67)66.67 (13.61 ) 2 0 Neutral Placebo 12 6.50 (2.45)16.67 (10.76) 3 mg 12 11.83 (2.68)50.00 (14.43) 4 mg 12 13.50 (2.61)50.00 (14.43) Note: Mean (SE) from SAS PROC UNIVARIATE. Percent (SE) from SAS PROC CATMOD
WO 95/28930 2 ~ 8 g ~ 8 J PCT/US95/04897 TABLE VIII B
Anova for Mean Erectile Function EFFECT DF F P-value Treatment 2.6611.560.0000 Stimulus 1.6637.140.0000 Treatment by Stimulus 2.660.10 0.9046 Contrasts Erotic: Placebo vs. Treatment 1.669.30 0.0033 Erotic: 3 mg vs. 4 mg 1.660.30 0.5849 Neutral: Placebo vs. Treatment 1.6613.030.0006 Neutral: 3 mg vs. 4 mg 1.660.71 0.4014 Note: Restricted maximum likelihood analysis performed using SAS PROC
MIXED.
TABLE VIII C
Logistic Regression for Percent Successful Erectile Function EFFECT DF X2 P-value Treatment 2 15.360.0005 Stimulus 1 5.14 0.0233 Treatment by Stimulus 2 0.00 1.0000 Contrasts Erotic: Placebo vs. Treatment 1 9.60 0.0019 Erotic: 3 mg vs. 4 mg 1 0.00 1.0000 3 0 Neutral: Placebo vs. Treatment 1 9.60 0.0019 Neutral: 3 mg vs. 4 mg 1 0.00 1.0000 Note: Analysis performed using .
SAS PROC CATMOD
~. _ . .._. _..._. _.____._ __..... _....... _._.._T , , TABLE IX
Visual Analogue Scale (VAS) (to be completed by the patient) Please mark each line clearly at the point which indicates how you are feeling right now.
Each line represents the full range of each feeling. (There are no right or wrong answers) Score (mm) 1. Alert Drowsy 2. Calm Excited 3. Yawning Not Yawning 4. Fuzzy Clear Headed 5. Well Coordinated Clumsy 6. Tired Energetic 7. Contented Disconnected 8. Troubled Tranquil 9. Mentally slow Quick Wetted 10. Tense Relaxed 11. Attentive Dreamy 2 0 12. Stomach Upset Feeling Well 13. Anxious Carefree (measure from left to right) Dose Evaluation Studv Clinical response to sublingual administration of apomorphine was evaluated utilizing a group of 60 non-vasculogenic impotent patients. Each patient had a history of erectile dysfunction for at least 3 months, normal biothesiometry response, and normal cavernosometry results.
The patients were divided into seven groups.
Each group received a predetermined dosage of apomorphine for 20 days in the form of apomorphine hydrochloride tablets 20 minutes prior to intercourse.
Seven different dosages were evaluated - 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg and 10 mg. The tablet constituents were those shown in Table I, above.
Assessment of response was made on the basis of the PC"T/US95/04897 patient's report of his experience. A response was deemed positive when the patient experienced an erection sufficiently rigid to effect penetration. Side effects such as nausea and/or vomiting, if present, were noted as well.
The results of this study are compiled in Table X, below.
TABLE X
1 o Results of Dose Evaluation Study Positive No. of Dosage, Responses Nausea Vomiting Patients mg No. % No. % No.
From the foregoing Table it can be seen that at a 4-mg dosage 40 percent of patients had a positive response, at a 5-mg dosage 50 percent of patients had a positive response, at 6-mg, 7-mg, and 8-mg dosages 70 percent of patients had a positive response and at a 10-mg dosage 80 percent of patients had a positive response. :iowever, the incidence of side effects increased as well as the dosage was increased.
The aforesaid apomorphine dosage forms are also well suited for diagnosing male human patients suffering from male erectile dysfunction. For diagnostic purposes, at least about 3 milligrams of apomorphine are administered sublingually to the patient 1 ~__... ~..._.. . . . ~_.__... T ~ .
and the patient is exposed to a visual erotic stimulus, e.g., an erotic videotape, while the patient's response thereto is monitored. If deemed desirable for diagnostic purposes, up to about 10 milligrams of apomorphine can be administered to the patient.
In particular, the patient's maximum increase in penile circumference (preferably tip as well as basal) is determined and the patient's maximum penile rigidity (preferably tip as well as basal) is determined. The determined circumferential increase and rigidity values are then compared against a predetermined base value. Equivalent methods of determining tumescence and rigidity can also be utilized.
The foregoing discussion and the reported studies are intended as illustrative of the present invention and are not to be taken as limiting. Still other variants within the spirit and scope of this invention are possible and will readily present themselves to those skilled in the art.
Claims (18)
1. An apomorphine dosage form that maintains circulating serum and midbrain tissue levels of apomorphine within a range so as to induce an erection adequate for vaginal penetration but so as not to induce substantial nausea.
2. The dosage form of claim 1 that is sublingual.
3. A composition for use in the manufacture of an apomorphine dosage form that maintains circulating serum and midbrain tissue levels of apomorphine within a range so as to induce an erection adequate for vaginal penetration but so as not to induce substantial nausea.
4. A method for diagnosing a male human patient suffering from erectile dysfunction which method comprises the steps of administering sublingually to the patient at least about 2.5 milligrams of apomorphine; and thereafter, in response to a visual erotic stimulus, determining the patient's maximum increase in penile circumference;
determining the patient's maximum penile rigidity; and comparing the determined maximum increase and maximum rigidity values against a predetermined base value for erectile dysfunction.
-Page 1 of Claims-
determining the patient's maximum penile rigidity; and comparing the determined maximum increase and maximum rigidity values against a predetermined base value for erectile dysfunction.
-Page 1 of Claims-
5. A diagnostic method in accordance with claim 4 wherein said maximum increase in penile circumference is determined by measuring penile tip circumference and penile basal circumference, and wherein said maximum rigidity is determined by measuring penile tip rigidity and penile basal rigidity.
6. The dosage form in accordance with claim 1 additionally containing a .beta.-cyclodextrin.
7. The dosage form in accordance with claim 6 wherein the .beta.-cyclodextrin is hydroxypropyl-.beta.-cyclodextrin.
8. Use of apomorphine or a pharmaceutically-acceptable acid addition salt thereof for the manufacture of a medicament for the amelioration of penile erectile dysfunction in psychogenic male patients, without inducing substantial nausea but enabling penetrative vaginal intercourse, by sublingual administration.
9. Use of apomorphine or a pharmaceutically-acceptable acid addition salt thereof according to claim 8, in a dosage amount of from 2 mg to 10 mg.
10. Use of apomorphine or a pharmaceutically-acceptable acid addition salt thereof according to claim 8 in a dosage amount of from 25 to 60 micrograms per kilogram of patient body weight.
-Page 2 of Claims-
-Page 2 of Claims-
11. Use as claimed in claim 8, 9 or 10 wherein the acid addition salt is apomorphine hydrochloride.
12. Use as claimed in claim 8, 9, 10 or 11 wherein administration of apomorphine or acid addition salt to the patient takes place over a time period in the range from 2 to minutes in a sublingual dose containing 25 to 60 micrograms of apomorphine or a pharmaceutically-acceptable acid addition salt thereof per kilogram of body weight.
13. Use as claimed in claim 8, 9, 10, 11 or 12 wherein the apomorphine or its acid addition salt is used in the form of a sublingual dosage form containing from 2.5 to 10 mg of apomorphine or its acid addition salt together with one or more tabletting excipients, said dosage form being one which dissolves in water within a time period of at least 2 minutes but less than 10 minutes.
14. Use as claimed in claim 13 wherein the dosage form includes a .beta.-cyclodextrin.
15. Use as claimed in claim 14 wherein the .beta.-cyclodextrin is hydroxypropyl-.beta.-cyclodextrin.
-Page 3 of Claims-
-Page 3 of Claims-
16. Use of apomorphine or a pharmaceutically-acceptable acid addition salt thereof for the manufacture of a diagnostic composition for diagnosis of penile erectile dysfunction by sublingual administration in an amount of at least 2.5 mg followed by (i) exposure of the patient to a visual erotic stimulus, (ii) determination of the maximum value for the resultant increase in patient penile circumference and the maximum value of the resultant patient penile rigidity and (iii) comparison of said values with respective predetermined base values indicative of erectile dysfunction, wherein said maximum increase in penile circumference is determined by measuring penile tip circumference and penile basal circumference, and wherein said maximum rigidity is determined by measuring penile tip rigidity and penile basal rigidity.
17. A sublingual apomorphine dosage form which dissolves in water within a time period of at least 2 minutes but less than 10 minutes and consists of 2 to 10 milligrams of apomorphine or its pharmaceutically-acceptable acid addition salt and one or more excipients.
18. Use of apomorphine or a pharmaceutically-acceptable acid addition salt thereof for the amelioration of penile -Page 4 of Claims-erectile dysfunction in psychogenic male patients without inducing substantial nausea.
-Page 5 of Claims-
-Page 5 of Claims-
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23125094A | 1994-04-22 | 1994-04-22 | |
| US231,250 | 1994-04-22 | ||
| PCT/US1995/004897 WO1995028930A1 (en) | 1994-04-22 | 1995-04-21 | Dosage forms and method for ameliorating male erectile dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2188385A1 CA2188385A1 (en) | 1995-11-02 |
| CA2188385C true CA2188385C (en) | 2000-07-11 |
Family
ID=22868404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002188385A Expired - Fee Related CA2188385C (en) | 1994-04-22 | 1995-04-21 | Dosage forms and method for ameliorating male erectile dysfunction |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US5770606A (en) |
| EP (2) | EP0978282B1 (en) |
| JP (1) | JP3310982B2 (en) |
| KR (1) | KR100374924B1 (en) |
| AT (2) | ATE189121T1 (en) |
| AU (1) | AU703608B2 (en) |
| CA (1) | CA2188385C (en) |
| DE (3) | DE69534693T2 (en) |
| DK (2) | DK0758895T3 (en) |
| ES (2) | ES2143049T3 (en) |
| GR (1) | GR3033084T3 (en) |
| HK (2) | HK1014239A1 (en) |
| LU (1) | LU90856I2 (en) |
| NL (1) | NL300072I1 (en) |
| PT (1) | PT758895E (en) |
| WO (1) | WO1995028930A1 (en) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| US6121276A (en) * | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| US20020165122A1 (en) * | 1994-04-22 | 2002-11-07 | Heaton Jeremy P. W. | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| US6395744B1 (en) | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US5624677A (en) * | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5888534A (en) * | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| AU751565B2 (en) * | 1995-06-13 | 2002-08-22 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| GB9514473D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
| EP0834308A1 (en) * | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
| DE19652268C2 (en) * | 1996-12-16 | 2000-06-29 | Lohmann Therapie Syst Lts | Medicinal preparation for the release of apomorphine in the oral cavity |
| GB9700878D0 (en) | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
| US6043252A (en) * | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
| CN1262622A (en) * | 1997-05-19 | 2000-08-09 | 佐纳根有限公司 | Combination therapy for modulating human sexual response |
| WO1998053819A1 (en) * | 1997-05-29 | 1998-12-03 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for erection failure |
| AU742787B2 (en) | 1997-07-09 | 2002-01-10 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
| US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
| US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
| DK1035833T3 (en) * | 1997-12-02 | 2006-01-09 | Archimedes Dev Ltd | Composition for nasal administration |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| AU2003204720B2 (en) * | 1998-05-29 | 2006-06-29 | Tap Pharmaceutical Products Inc. | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| US6436950B1 (en) * | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
| US20020002175A1 (en) * | 2000-09-19 | 2002-01-03 | Charanjit Behl | Nasal delivery of apomorphine in combination with glycol derivatives |
| US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
| CA2340206A1 (en) | 1998-08-26 | 2000-03-09 | Queen's University At Kingston | Use of anti-pressor agents for vascular remodeling in genital dysfunction |
| US20040063719A1 (en) * | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
| US6291471B1 (en) * | 1998-12-17 | 2001-09-18 | Abb Holdings, Inc. | Use of apomorphine for the treatment of organic erectile dysfunction in males |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| AU3490300A (en) * | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
| US7577475B2 (en) * | 1999-04-16 | 2009-08-18 | Cardiocom | System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus |
| US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
| SI1225881T1 (en) * | 1999-09-03 | 2006-06-30 | Apbi Holdings Llc | The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction |
| BR0109515A (en) | 2000-04-07 | 2004-08-10 | Tap Pharmaceutical Prod Inc | Apomorphine Derivatives and Methods for Their Use |
| WO2002007757A2 (en) * | 2000-07-21 | 2002-01-31 | Lue Tom F | Prevention and treatment of sexual arousal disorders |
| US7223406B2 (en) * | 2000-07-21 | 2007-05-29 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
| FR2813193B1 (en) * | 2000-08-25 | 2003-08-15 | Pelvipharm | MEDICINE FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS BY ACTION ON THE CENTRAL NERVOUS SYSTEM |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| CZ20031540A3 (en) | 2000-11-15 | 2004-05-12 | Tapápharmaceuticaláproductsźáinc | Medicament for treating sexual dysfunction |
| US20020103105A1 (en) * | 2000-11-22 | 2002-08-01 | Brioni Jorge D. | Use of selective dopamine D4 receptor agonists for treating sexual dysfunction |
| EP1224933A1 (en) * | 2001-01-19 | 2002-07-24 | Sanofi-Synthelabo | New combination of active ingredients containing alfuzosine and apomorphine |
| NZ527113A (en) * | 2001-02-08 | 2005-04-29 | Pharmacia Corp | Rapid-onset medicament for the treatment of sexual dysfunction |
| US20030187011A1 (en) * | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
| ES2271542T3 (en) * | 2002-02-07 | 2007-04-16 | Pharmacia Corporation | PHARMACEUTICAL DOSAGE FORM FOR ADMINISTRATION BY THE MUCOSA. |
| JP2005526790A (en) * | 2002-03-19 | 2005-09-08 | ミシェル ホリック | Apomorphine and analog glycosides and orthoester glycoside derivatives, and methods of use thereof |
| WO2003101358A1 (en) * | 2002-05-31 | 2003-12-11 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine |
| GB0221711D0 (en) * | 2002-09-19 | 2002-10-30 | Ardana Bioscience Ltd | Methods |
| CA2445212A1 (en) * | 2002-10-10 | 2004-04-10 | Queen's University At Kingston | Treatment of sexual dysfunction |
| GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
| US7943632B2 (en) * | 2003-03-17 | 2011-05-17 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| ZA200507877B (en) * | 2003-03-31 | 2007-01-31 | Titan Pharmaceuticals Inc | Implantable polymeric device for sustained release of dopamine agonist |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| WO2004089374A1 (en) * | 2003-04-14 | 2004-10-21 | Vectura Ltd | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
| ATE444953T1 (en) * | 2003-06-17 | 2009-10-15 | Janssen Pharmaceutica Nv | SUBSTITUTED SPIROBENZAZEPINES |
| AU2006299833B2 (en) | 2005-10-12 | 2012-04-12 | Besins Healthcare Luxembourg Sarl | Improved testosterone gel and method of use |
| JP2009523806A (en) * | 2006-01-20 | 2009-06-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | (4R) -1- [4- (2-Chloro-5-fluorobenzoyl) amino-3-methoxybenzoyl] -1,2,3,5-tetrahydro-spiro [4H-1-benzazepine-4,1′- [2] Novel solid form of cyclopentene] -3'-carboxylic acid |
| GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| CN102480958B (en) * | 2009-06-12 | 2015-08-19 | Cynapsus疗法有限公司 | sublingual apomorphine |
| CA2821756C (en) | 2010-12-16 | 2021-06-29 | Cynapsus Therapeutics, Inc. | Sublingual films comprising apomorphine and an organic base |
| JP2016535794A (en) * | 2013-11-11 | 2016-11-17 | インパックス ラボラトリーズ，インコーポレーテッド | Rapidly disintegrating preparations and methods of use |
| AU2015274462A1 (en) * | 2014-06-12 | 2016-12-22 | University Of Notre Dame Du Lac | Composition and method for the treatment of neurological diseases and cerebral injury |
| CA3127926A1 (en) | 2015-04-21 | 2016-10-27 | Sunovion Pharmaceuticals Inc. | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
| WO2020180424A1 (en) | 2019-03-04 | 2020-09-10 | Iocurrents, Inc. | Data compression and communication using machine learning |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2818855A (en) * | 1954-02-11 | 1958-01-07 | Anthony P Miller | Surgical device |
| US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4543256A (en) * | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
| US4687773A (en) * | 1983-03-28 | 1987-08-18 | Mclean Hospital | (+)-N-N-propylnorapomorphine and selective limbic activity |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
| US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| DE69434304T2 (en) * | 1993-03-26 | 2005-12-29 | Merkus, Franciscus Wilhelmus H.M. | Pharmaceutical compositions for the intranasal administration of dihydroergotamine |
-
1995
- 1995-04-21 CA CA002188385A patent/CA2188385C/en not_active Expired - Fee Related
- 1995-04-21 ES ES95916467T patent/ES2143049T3/en not_active Expired - Lifetime
- 1995-04-21 AT AT95916467T patent/ATE189121T1/en active
- 1995-04-21 AT AT99121684T patent/ATE312609T1/en not_active IP Right Cessation
- 1995-04-21 KR KR1019960705906A patent/KR100374924B1/en not_active IP Right Cessation
- 1995-04-21 EP EP99121684A patent/EP0978282B1/en not_active Expired - Lifetime
- 1995-04-21 DK DK95916467T patent/DK0758895T3/en active
- 1995-04-21 ES ES99121684T patent/ES2256999T3/en not_active Expired - Lifetime
- 1995-04-21 EP EP95916467A patent/EP0758895B1/en not_active Expired - Lifetime
- 1995-04-21 PT PT95916467T patent/PT758895E/en unknown
- 1995-04-21 DE DE69534693T patent/DE69534693T2/en not_active Expired - Fee Related
- 1995-04-21 WO PCT/US1995/004897 patent/WO1995028930A1/en active IP Right Grant
- 1995-04-21 AU AU22958/95A patent/AU703608B2/en not_active Ceased
- 1995-04-21 JP JP52777595A patent/JP3310982B2/en not_active Expired - Fee Related
- 1995-04-21 DE DE2001199068 patent/DE10199068I2/en active Active
- 1995-04-21 DK DK99121684T patent/DK0978282T3/en active
- 1995-04-21 DE DE69514794T patent/DE69514794T2/en not_active Expired - Lifetime
- 1995-10-20 US US08/546,498 patent/US5770606A/en not_active Expired - Fee Related
-
1998
- 1998-06-22 US US09/102,235 patent/US5985889A/en not_active Expired - Fee Related
- 1998-12-24 HK HK98115585A patent/HK1014239A1/en not_active IP Right Cessation
- 1998-12-24 HK HK00104970A patent/HK1025742A1/en not_active IP Right Cessation
-
1999
- 1999-11-15 US US09/440,451 patent/US6200983B1/en not_active Expired - Fee Related
-
2000
- 2000-03-28 GR GR20000400773T patent/GR3033084T3/en not_active IP Right Cessation
-
2001
- 2001-11-23 LU LU90856C patent/LU90856I2/en unknown
- 2001-11-27 NL NL300072C patent/NL300072I1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2188385C (en) | Dosage forms and method for ameliorating male erectile dysfunction | |
| US6306437B1 (en) | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction | |
| Comer et al. | Depot naltrexone: long-lasting antagonism of the effects of heroin in humans | |
| AU752928B2 (en) | Treatment of female sexual dysfunction | |
| KR100719977B1 (en) | Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction | |
| PL185528B1 (en) | Methods of and formulations for modulating human sexual response | |
| US6566368B2 (en) | Apomorphine-containing dosage form for ameliorating male erectile dysfunction | |
| Greenwald et al. | Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study | |
| Weber | Transdermal antihypertensive therapy: clinical and metabolic considerations | |
| CN109310691A (en) | For quickly starting the dosage regimen of antidepressant effect | |
| CZ20004653A3 (en) | Apomorphine and antiemetic intended for use in therapy, apomorphine mixture, antiemetics, and medicamentous form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |